Lancet Diabetes & Endocrinology

Article	Citations
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study	671
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study	642
Epidemiology and determinants of obesity in China	626
COVID-19 in people with diabetes: understanding the reasons for worse outcomes	624
Practical recommendations for the management of diabetes in patients with COVID-19	604
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials	442
Endocrine-disrupting chemicals: implications for human health	358
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study	333
Causes, consequences, and treatment of metabolically unhealthy fat distribution	316
Consensus on diagnosis and management of Cushing's disease: a guideline update	310
Risks and burdens of incident diabetes in long COVID: a cohort study	296
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression	289
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial	286
Screening for diabetic retinopathy: new perspectives and challenges	284
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials	269
Thyroid cancer incidence trends by histology in 25 countries: a population-based study	249
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study	242
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials	234
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland	233
A global view of the interplay between non-alcoholic fatty liver disease and diabetes	231
Obesity in children and adolescents: epidemiology, causes, assessment, and management	229
SARS-CoV-2-related atypical thyroiditis	202
Gestational diabetes: opportunities for improving maternal and child health	199
Global trends in thyroid cancer incidence and the impact of overdiagnosis	198
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study	190

Polycystic ovary syndrome	189
Type 2 diabetes and cognitive dysfunction—towards effective management of both comorbidities	188
Prevalence of obesity among adult inpatients with COVID-19 in France	187
Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial	183
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	178
Association between high serum total cortisol concentrations and mortality from COVID-19	177
Vitamin-D and COVID-19: do deficient risk a poorer outcome?	173
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records	171
Health policy and public health implications of obesity in China	167
Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study	163
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial	162
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomi	158
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group	155
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study	155
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial	155
COVID-19 and metabolic disease: mechanisms and clinical management	153
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	144
Endocrine-disrupting chemicals: economic, regulatory, and policy implications	144
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study	143
Vitamin D for COVID-19: a case to answer?	143
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial	141
RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	137
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England	136
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study	135
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating	131
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery	126
Bone fragility in diabetes: novel concepts and clinical implications	126
Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis	125
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study	125
Management of diabetes and hyperglycaemia in the hospital	125
Central nervous pathways of insulin action in the control of metabolism and food intake	124
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes	122
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials	118
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	109
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase	108
Diagnosis and treatment of primary aldosteronism	108
Clinical management and treatment of obesity in China	105
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial	104
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care	103
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomise	102
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial	100
Nutritional intake and bone health	98
Diabetes, metabolic disease, and telomere length	97
Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases	96
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	94
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase	93
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	89
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial	89
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	89
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multic	88

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial	85
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study	85
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings	84
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial	84
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials	83
A telehealth lifestyle intervention to reduce excess gestational weight gain in pregnant women with overweight or obesity (GLOW): a randomised, parallel-group, controlled trial	82
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial	79
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o	79
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality	78
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction	78
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial	76
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	76
Sexual dimorphism in COVID-19: potential clinical and public health implications	76
The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement	75
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	74
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial	74
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial	70
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)	69
Health care and mental health challenges for transgender individuals during the COVID-19 pandemic	66
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	66
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	66
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	65
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study	64
Menopause: a cardiometabolic transition	63
Glycaemic status during pregnancy and longitudinal measures of fetal growth in a multi-racial US population: a prospective cohort study	61
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial	61
Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria	59
Osteoporosis in men	59
Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series	58
Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals	58
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study	58
Diagnosis of thyroid nodules	58
A worldwide journey of thyroid cancer incidence centred on tumour histology	57
Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study	56
Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study	55
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial	55
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study	53
Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide—for type 1 diabetes	53
Adrenal myelolipomas	52
Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis	52
Obesity in people living with type 1 diabetes	52
Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies	52
Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study	52
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	51
Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study	51
Glycaemic management in diabetes: old and new approaches	50
Catecholamine physiology and its implications in patients with COVID-19	49
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	48
Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study	48
Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study	48
Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes	48
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials	46
Acromegaly: pathogenesis, diagnosis, and management	45
COVID-19 and obesity—lack of clarity, guidance, and implications for care	44
European Commission classifies obesity as a chronic disease	44
Diabetes in ageing: pathways for developing the evidence base for clinical guidance	44
Insulin's centenary: the birth of an idea	43
Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study	43
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	43
Mapping overdiagnosis of thyroid cancer in China	42
Management of menopause: a view towards prevention	42
COVID-19 and diabetes: a co-conspiracy?	42
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study	42
The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial	41
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	41
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	41
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism	41
COVID-19 targets human adrenal glands	40
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial	40
COVID-19 vaccine prioritisation for type 1 and type 2 diabetes	39
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	39
Thyroid cancer in the USA: current trends and outstanding questions	38
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data	38
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	38
Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection	37
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	37
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial	36
Obesity and COVID-19: a call for action from people living with obesity	36
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial	36
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	34

The WHO Global Diabetes Compact: a new initiative to support people living with diabetes	34
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study	33
Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature	33
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	33
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records	32
Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study	32
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study	32
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study	32
COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way	31
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment	31
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis	30
Vitamin D and COVID-19: why the controversy?	30
Associations between androgens and sexual function in premenopausal women: a cross-sectional study	30
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmoniz	29
Gestational diabetes and fetal overgrowth: time to rethink screening guidelines	29
The link between type 2 diabetes and dementia: from biomarkers to treatment	29
The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery	29
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	28
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised,	28
How fossil fuel-derived pesticides and plastics harm health, biodiversity, and the climate	28
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the	27
Adrenal crises in older patients	27
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial	27
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	27
Knowledge gaps and weight stigma shape attitudes toward obesity	26
Management of thyroid nodules	26
Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome: the HUNT study	26
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis	26
Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study	25
Childhood obesity: a growing pandemic	25
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT	24
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	24
Subclinical hypothyroidism in older individuals	24
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	23
Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes?	22
Menopause transition: a golden age to prevent cardiovascular disease	22
Obesity in China: time to act	22
Walking the path together: incorporating Indigenous knowledge in diabetes research	21
Challenges in investigating risk factors for thyroid cancer	21
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	21
COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess	21
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study	20
Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey	20
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	20
How diabetes management is adapting amid the COVID-19 pandemic	20
FDA approves teplizumab: a milestone in type 1 diabetes	20
Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study	20
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study	20
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial	19
Vitamin D: 100 years of discoveries, yet controversy continues	19
β-cell secretory dysfunction: a key cause of type 2 diabetes	19
Ultra-processed food: a global problem requiring a global solution	19
Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering	19
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis	18
Osteoporosis: overlooked in men for too long	18
Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study	18
Treating chronic diseases without tackling excess adiposity promotes multimorbidity	17
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou	17
The relevance of T3 in the management of hypothyroidism	17
COVID-19: underlying metabolic health in the spotlight	17
Food security and nutrition in the world	17
Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications	17
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study	17
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement	17
Back to normal? Building community resilience after COVID-19	17
Diabetes after SARS-CoV-2 infection	17
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study	17
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme	17
Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohor	17